Table 1. Demographic, clinical and genetic features of the early detection cohort.
| Gender | n | % | Ten-gene multiplex positive | TERT positive | Aneuploidy positive | UroSEEK positive | Cytology positive* | Uroseek or cytology positive* |
|---|---|---|---|---|---|---|---|---|
| Table 1a. Demographic, clinical and genetic features of the early detection cohort | ||||||||
| Males without recurrence | 172 | 59% | 3 (2%) | 10 (6%) | 2 (1%) | 13 (8%) | 0 (0%) | 13 (8%) |
| Males with recurrence | 32 | 11% | 26 (81%) | 21 (66%) | 19 (59%) | 29 (91%) | 16 (50%) | 30 (94%) |
| Females without recurrence | 81 | 28% | 2 (2%) | 2 (2%) | 1 (1%) | 5 (6%) | 0 (0%) | 5 (6%) |
| Females with recurrence | 9 | 3% | 4 (44%) | 4 (44%) | 3 (33%) | 6 (67%) | 1 (11%) | 6 (67%) |
| Indication | ||||||||
| Hematuria without recurrence | 346 | 61% | 6 (2%) | 15 (4%) | 5 (1%) | 22 (6%) | 0 (0%) | 17 (5%) |
| Hematuria with recurrence | 163 | 29% | 108 (66%) | 90 (55%) | 76 (47%) | 134 (82%) | 18 (11%) | 32 (2%) |
| LUTS without recurrence | 11 | 2% | 0 (0%) | 2 (18%) | 0 (0%) | 2 (18%) | 0 (0%) | 2 (18%) |
| LUTS with recurrence | 3 | 1% | 2 (67%) | 1 (33%) | 0 (0%) | 2 (67%) | 1 (33%) | 2 (67%) |
| Other without recurrence | 38 | 7% | 1 (3%) | 0 (0%) | 1 (3%) | 2 (5%) | 0 (0%) | 2 (5%) |
| Other with recurrence | 9 | 2% | 9 (100%) | 8 (89%) | 5 (56%) | 9 (100%) | 2 (22%) | 9 (100%) |
| Detected Tumor Diagnosis | ||||||||
| PUNLMP | 2 | 1% | 0 (0%) | 1 (50%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) |
| CIS | 7 | 5% | 4 (57%) | 4 (57%) | 1 (14%) | 6 (86%) | 3 (43%) | 6 (86%) |
| LGTCC | 31 | 21% | 15 (48%) | 18 (58%) | 9 (29%) | 22 (71%) | 0 (0%) | 4 (13%) |
| HGTCC | 49 | 33% | 34 (69%) | 28 (57%) | 26 (53%) | 40 (82%) | 4 (8%) | 11 (22%) |
| INTCC | 61 | 41% | 48 (79%) | 36 (59%) | 35 (57%) | 57 (93%) | 9 (15%) | 16 (26%) |
| Cytology diagnosis* | ||||||||
| Positive | 21 | 6% | 16 (76%) | 12 (57%) | 16 (76%) | 20 (95%) | N/A | N/A |
| Atypical | 105 | 30% | 21 (20%) | 21 (30%) | 12 (11%) | 30 (29%) | N/A | N/A |
| Negative | 221 | 64% | 4 (2%) | 9 (4%) | 1 (0.4%) | 12 (5%) | N/A | N/A |
| Table 1b. Demographic, clinical and genetic features of the Surveillance cohort. | ||||||||
| Males without recurrence | 59 | 30% | 3 (5%) | 8 (14%) | 3 (5%) | 10 (17%) | 0 (0%) | 8 (14%) |
| Males with recurrence | 90 | 45% | 45 (50%) | 53 (59%) | 20 (22%) | 59 (66%) | 20 (22%) | 53 (59%) |
| Females without recurrence | 17 | 9% | 5 (29%) | 3 (18%) | 0 (0%) | 6 (35%) | 0 (0%) | 6 (35%) |
| Females with recurrence | 33 | 17% | 15 (45%) | 19 (58%) | 11 (33%) | 33 (100%) | 6 (18%) | 19 (58%) |
| Original Tumor Diagnosis | ||||||||
| PUNLMP | 12 | 4% | 5 (42%) | 2 (17%) | 1 (8%) | 6 (50%) | 0 (0%) | 2 (17%) |
| CIS | 25 | 8% | 11 (44%) | 13 (52%) | 6 (24%) | 14 (56%) | 5 (20%) | 10 (40%) |
| LGTCC | 107 | 35% | 27 (25%) | 34 (32%) | 8 (7%) | 41 (38%) | 0 (0%) | 59 (55%) |
| HGTCC | 62 | 20% | 22 (36%) | 24 (39%) | 10 (16%) | 30 (49%) | 4 (7%) | 16 (26%) |
| INTCC | 104 | 34% | 39 (38%) | 47 (45%) | 29 (28%) | 54 (52%) | 20 (19%) | 34 (33%) |
| Original Tumor Stage | ||||||||
| pTis | 25 | 8% | 11 (44%) | 13 (52%) | 6 (24%) | 14 (56%) | 5 (20%) | 10 (40%) |
| pTa | 181 | 58% | 54 (30%) | 60 (33%) | 19 (19%) | 77 (43%) | 4 (2%) | 77 (43%) |
| pT1 | 71 | 23% | 28 (39%) | 35 (49%) | 22 (31%) | 39 (55%) | 14 (20%) | 23 (32%) |
| pT2 | 23 | 7% | 9 (9%) | 9 (39%) | 7 (30%) | 12 (52%) | 5 (22%) | 10 (43%) |
| pT3 | 9 | 3% | 1 (11%) | 2 (22%) | 0 | 2 (22%) | 1 (11%) | 1 (11%) |
| pT4 | 1 | 0.3% | 1 (100%) | 1 (100%) | 0 | 1 (100%) | N/A | N/A |
| Routine cytology diagnosis* | ||||||||
| Positive | 30 | 15% | 21 (21%) | 25 (83%) | 20 (67%) | 27 (90%) | N/A | N/A |
| Atypical | 95 | 48% | 38 (40%) | 43 (45%) | 18 (19%) | 50 (53%) | N/A | N/A |
| Negative | 71 | 36% | 12 (17%) | 13 (18%) | 3 (4%) | 19 (27%) | N/A | N/A |
*Cytology was available on only a subset of cases.
N/A Not Available.